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Figure 4. 
Adapted from Heller and Cryer Diabetes 1991 
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Abstract: Despite the introduction of newer technologies and improved insulin 
formulations, recurrent hypoglycaemia continues to affect the lives of many 
people with types 1 and 2 diabetes. Developing strategies or therapies designed 
to prevent or minimise hypoglycaemia risk is of outmost importance to help 
individuals safely achieve glycaemic targets. Novel, educational or behavioural 
approaches need to be based on a clear understanding of the mechanisms 
underpinning both the detection of hypoglycaemia and why repeated exposure 
to hypoglycaemia leads to the development of a clinical syndrome referred to as 
impaired awareness of hypoglycaemia (IAH). In this lecture, I propose that IAH 
may represent a form of learning called habituation; a response that at a cellular 
level represents a biological adaptation designed to protect the organism from 
future exposure to that stressor. In diabetes, this survival response to low 
glucose is, however, overwhelmed by high systemic insulin levels resulting from 
exogenous insulin therapy, leading to progressively more severe hypoglycaemia.  
Recognition of the underlying mechanism means that the development of IAH 
can perhaps be better understood and explained to individuals with diabetes, 
and novel therapeutic approaches such as dishabituation or cognitive 
behavioural therapies can be considered. 
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Introduction 
Soon after the successful use of insulin in humans, physicians began to recognise 
that excessive insulin replacement lead to more marked falls in blood glucose 
and when the glucose fell below approximately 3.9 mmol/l the patient would 
become aware of hypoglycaemia with ‘a characteristic train of symptoms’ that 
became known as the ‘hypoglycaemic reaction’[1]. RD Lawrence, in honour of 
whom this lecture is given, subsequently made the important observation in 
1941 that the symptoms of hypoglycaemia changed over time and in fact 
‘reactions differ so much from the original ones that patients become 
dangerously unaware of their onset’ [2]. This clinical phenomenon, came initially 
to be known as ‘hypoglycaemia unawareness’, but is now more appropriately 
referred to as ‘impaired awareness of hypoglycaemia’ (IAH). IAH is defined as ‘a 
diminished ability to perceive the onset of acute hypoglycaemia’ [3].  It is not a 
condition that is either present or absent in an individual, but reflects a 
continuum in which differing degrees of IAH can occur and can vary over time in 
any one individual. Why this happens in people with diabetes, and the 
mechanisms(s) that underpin this, remains unknown and will be the subject of 
this article. 
The thesis of this lecture is that IAH results from co-ordinated intra- and extra-
cellular physiological adaptations to recurrent hypoglycaemic stress that are in 
essence survival responses designed to protect the cell from subsequent 
exposure to glucose deprivation. I will also make the argument that these 
adaptations at the cellular level can be considered a form of learning that 
ultimately lead to a change in behaviour as well as physiological responses in 
humans. This change appears to bear the hallmarks of a behavioural response 
that is commonly referred to as ‘habituation’.  Therefore, this lecture will 
propose that habituation to hypoglycaemia may provide a paradigm in which we 
can consider how humans respond to recurrent hypoglycaemia and 
subsequently the approaches that may help in reversing this condition. 
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Hypoglycaemia in Clinical Practice 
Hypoglycaemia is rare in people without diabetes, but due to fundamental 
defects in the mechanisms that regulate glucose homeostasis it is an all too 
common event in those with Type 1 (T1D) [4]. Mild hypoglycaemia is thought to 
occur on average about once or twice weekly [5], while severe hypoglycaemia 
(defined as the need for external assistance to recover)  is experienced on 
average 1-3 times per person-year depending on duration of T1D. (e.g.[6]). Many 
people with T1D will not experience severe hypoglycaemia, and the average rate 
reflects a higher frequency of events in a small cohort of people.  
 
Severe hypoglycaemia has a well-recognised morbidity and mortality in T1D [7], 
while, more recently, a concern has also been raised about the possible 
consequences of hypoglycaemia in people with T2D and established 
cardiovascular disease [8, 9]. However, it is important to also recognise that 
hypoglycaemia has more widespread effects on the brain, inducing a negative 
mood state (tense-tiredness) as well as negative appraisals of a life circumstance 
[10]. It is because of these emotional and cognitive effects of hypoglycaemia, in 
addition to the potentially catastrophic effects of severe hypoglycaemia, that 
many people with diabetes try to avoid ever becoming hypoglycaemic even if it is 
at the expense of poor overall glycaemic control.  
 
Impaired awareness of hypoglycaemia is thought to effect around 20-25% of all 
people with T1D (Figure 1), and is generally more prevalent in older subjects 
with longer duration of T1D (e.g.[11]). Interestingly, it is less clearly associated 
with overall glycaemic control [11], although may develop following a period of 
rapid improvement in HbA1c with intensification of therapy [12]. Clinically, it is 
important to recognise because most studies report a significantly higher risk of 
severe hypoglycaemia (up to x6-fold) in those subjects with IAH [11].  
 
Why does hypoglycaemia develop in Type 1 Diabetes? 
In the main, glucose homeostasis is regulated by the fine balance between the 
glucose lowering action of insulin and the opposing actions of glucagon, both 
secreted in a co-ordinated manner by pancreatic beta- and alpha cells 
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respectively.   In T1D, the destruction of pancreatic beta cells results in the need 
for insulin replacement that is usually delivered to the circulation from a 
subcutaneous depot following injection or infusion.  This creates two major 
physiological problems in the context of hypoglycaemia. Firstly, peripheral 
rather than portal delivery of insulin means that to reach insulin levels in the 
portal vein sufficient to suppress hepatic glucose production requires systemic 
hyperinsulinaemia. This provides an additional stimulus to enhance glucose 
uptake into peripheral insulin-sensitive tissues increasing the risk of 
hypoglycaemia. Secondly there is also a loss of feedback suppression of insulin 
secretion when glucose levels fall. Effectively, the T1D individual is unable to 
supress exogenous insulin release during developing hypoglycaemia and its 
glucose lowering action therefore continues.  
 
In addition, alpha-cell glucagon secretion is also fundamentally disturbed in T1D 
[13]. People with T1D do not secrete glucagon, the primary counterregulatory 
hormone in response to a hypoglycaemic challenge [13], a defect that is present 
in nearly all people with T1D by 5 years disease duration [14]. The reason for 
this remains unknown though is thought to reflect loss of an intra-islet signal 
that follows beta-cell destruction (for review see [4]). Interestingly, basal and 
post-prandial glucagon levels are increased in T1D implying that the alpha-cell is 
in some ways behaving like a beta-cell, i.e. classical stimulus-secretion coupling 
occurs and high glucose stimulates glucagon release whereas low glucose 
supresses it. This profound disturbance in islet structure and function explains 
why hypoglycaemia is far more likely to occur in people with T1D but it does not 
explain why the symptom-complex of hypoglycaemia changes overtime. For this 
we now turn to a series of very elegant studies performed in in the late 1980s 
and early 1990’s. 
 
We Are What We Repeatedly Do 
Early studies using insulin infusions in people with T1D showed that with longer 
duration of T1D in addition to abnormal glucagon secretion, many subjects also 
produced a less robust catecholaminergic (adrenaline and noradrenaline) 
response to hypoglycaemia [15]. In examining why this latter defect developed, 
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Amiel [12] discovered that intensification of therapy raised the threshold 
(lowered the glucose level) at which the counterregulatory catecholamines were 
released in response to hypoglycaemia (Figure 2), and this was followed by the 
seminal work of Heller [16] demonstrating that prior exposure to hypoglycaemia 
itself was the principal reason for this. Thus, increasing duration of disease and 
in particular exposure to recurrent episodes of hypoglycaemia appeared to 
result in further suppression of the hormonal (catecholaminergic) and related 
autonomic symptomatic response to subsequent hypoglycaemia (Figure 3). 
 
This latter work in particular led to the proposal by Cryer and the subject of his 
1994 Banting Lecture to the American Diabetes Association [17] that antecedent 
iatrogenic hypoglycaemia was the  major factor that lead to the development of 
impaired awareness of hypoglycaemia. He coined the term Hypoglycaemia-
Associated Autonomic Failure (HAAF), to describe the constellation of 
physiological responses to recurrent hypoglycaemia, namely defective glucose 
counterregulation (the result of combined deficiencies of the glucagon and 
adrenaline responses to falling glucose levels), impaired awareness of 
hypoglycaemia (loss of the warning, neurogenic symptoms of developing 
hypoglycaemia), and elevated glycaemic thresholds (lower glucose levels 
required) for autonomic activation and symptoms during effective intensive 
therapy [17]. He would also later add exercise [18] and sleep [19] as related 
parts of HAAF because both led independently to impaired counterregulation. 
Cryer considered HAAF to be ‘maladaptive’, because it increased an individual’s 
risk of severe hypoglycaemia. However, HAAF really only describes a series of 
physiological responses to recurrent hypoglycaemia in humans and provides 
little information on why this develops. To try and answer this question the 
1990s and naughties saw a series of studies, largely in animal models that 
attempted to understand a little more of the molecular biology that underpinned 
hypoglycaemia detection and response to recurrent hypoglycaemia.  
 
How and where do we detect hypoglycaemia? 
In order to understand the mechanisms underpinning HAAF, the next two 
decades saw a series of studies in animal models that examined where the body 
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detected a falling glucose and what mechanisms were employed to detect 
hypoglycaemia. This area is reviewed elsewhere and will not be addressed in any 
detail in this article (see [4] for a recent review). What we have learnt from this 
work is that the detection of hypoglycaemia actually takes place in many distinct 
regions of the body that together form a network of specialised glucose sensing 
neurons [20]. Of these regions, the brain is perhaps most critical given its high 
energy demands relative to the body as a whole and the near absolute 
requirement of the brain for glucose as a fuel source. 
 
In the brain, glucose-sensing regions contain specialized neurons that sense 
fluctuations in the glucose levels to which they are exposed and, critically, 
translate this into a change in membrane potential and action potential activity. 
Changes in neural activity then signal to effector organs such as liver or muscle 
where subsequent changes in glucose uptake or output help maintain or restore 
glucose homeostasis. Interestingly, like the pancreatic beta-cell, these neurons 
use the pancreatic isoform of glucokinase (GK) as a rate limiting step in glucose 
sensing and SUR-1 selective ATP-sensitive potassium channel (KATP) to translate 
the ATP-signal into a change in K+ flux and hence a change in membrane 
potential, firing frequency and network activity [4]. Although, this research is 
mainly cell or animal based, a recent study from our laboratory have confirmed 
that these same mechanisms are also integral to hypoglycaemia detection in 
people with type 1 diabetes [21].  
 
Why does exposure to recurrent hypoglycaemia lead to impaired glucose 
sensing? 
 
This basic and preclinical research performed in animal models led to the 
recognition that changes within key glucose sensing regions of the brain such as 
the hypothalamus were instrumental in the development of impaired 
hypoglycaemia sensing in type 1 diabetes [22, 23]. What is less clear is why the 
glucose sensing properties of these neurons change following exposure to 
recurrent hypoglycaemia. Proposed mechanisms have included an increase in 
the uptake or metabolism of glucose and/ or the alternate fuel lactate, increased 
Page 12 of 25Diabetic Medicine
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
release of the inhibitory neurotransmitter, GABA, or an external signal such as 
glucocorticoid-mediated suppression of glucose sensing neurons (reviewed in [4, 
24]). While these mechanisms probably all contribute at least in part to the 
development of impaired glucose sensing, as yet no clear understanding of the 
mechanism that drives defective counterregulation has emerged.  
 
During insulin-induced hypoglycaemia glucose levels in the extra-cellular space 
in both rodents and humans fall dramatically and are approximately 10% of 
plasma levels [25, 26]. This degree of glucose (energy) deprivation represents a 
profound physiological challenge to the cell as is evident from the marked 
counterregulatory response hypoglycaemia stimulates in humans without 
diabetes. It therefore seems likely that in response to this challenge neurons will 
initiate a survival response that is designed to both prevent cell death and 
prepare to neuron so that it is better able to survive future episodes of profound 
glucose (energy) deprivation [24]. Consistent with this, rats exposed to repeated 
moderate hypoglycaemia show less neuronal cell death during subsequent 
severe hypoglycaemia that their controls [27]. This biological process is often 
referred to as pre-conditioning, a neuroprotective response that induces 
tolerance to the physiological stressor (in this case hypoglycaemia) [24]. Pre-
conditioning is not unique to hypoglycaemia and is a highly conserved means by 
which cells respond to varied homeostatic challenges such as energy 
deprivation, ischaemia or temperature extremes. The problem in type 1 diabetes 
is that this biological adaptation occurs within the unphysiological context of 
high circulating insulin levels and ultimately no matter how well adapted 
neurons have become hypoglycaemia of sufficient degree will lead progressively 
to cognitive dysfunction and then cell death. Therefore, in essence a highly 
conserved biological adaptation to energy deprivation occurs but in an 
unphysiological context in type 1 diabetes (unregulated hyperinsulinaemia and 
absent glucagon responses) and this drives glucose down to levels that cannot 
sustain neuronal function so severe hypoglycaemia ensues. 
 
 
 
Page 13 of 25 Diabetic Medicine
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Hypoglycaemia Habituation 
 In the preceding discussion, I have proposed that at a biological level, recurrent 
hypoglycaemia may provide a pre-conditioning stimulus that initiates cellular 
adaptations designed to protect the cell during subsequent exposure to that 
same stimulus (tolerance). Hypoglycaemia in humans initiates far more than 
simple biological responses. Integrated physiological (counterregulatory 
hormonal), symptomatic (autonomic and neuroglycopenic symptoms), and 
behavioural (food seeking) responses are all activated by acute hypoglycaemia 
and can all be affected by recurrent hypoglycaemia. For instance, driving 
performance in T1D is significantly disrupted at relatively mild hypoglycaemia, 
yet subjects demonstrate a hesitation to take corrective action, i.e. judgement is 
impaired and the appropriate behavioural response not initiated [28]. 
 
In the 1940s scientists were looking for simple models in which they could try to 
gain some understanding of the neuronal mechanisms underlying more complex 
behavioural change. Thompson and Spencer provided a detailed and informative 
review of this area in the 1960’s by considering the phenomenon of ‘habituation’ 
that had been studied through simple responses such as the sensory-motor 
reflex in cats [29]. Eric Kandel, who received the Nobel Prize in Physiology or 
Medicine in 2000, exemplified this approach through his pioneering research 
into the gill and siphon withdrawal reflex (GSWR) of Aplysia californica (a large 
shell-less sea snail or sea slug), in the 1960s and 1970s. The GSWR is an 
involuntary, defensive reflex that causes the sea hare's delicate siphon and gill to 
be retracted when the animal is disturbed. Repeated stimulation of the GSWR 
eventually results in a progressive decrease in the response; the process referred 
to as habituation.  
 
Thompson and Spencer, proposed that habituation was a ‘reduction of the 
psychological, behavioural or physiological response to a stimulus as a result of 
repeated or prolonged exposure’ [29]. They described nine features that were 
characteristic of habituation, and we will consider these now in the context of 
recurrent hypoglycaemia. 
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1. Given that a particular stimulus elicits a response, repeated applications of 
that stimulus result in a decreased response (Habituation). For 
hypoglycaemia this means that for habituation to have occurred repeated 
hypoglycaemia should result eventually in a diminished response to 
hypoglycaemia in that individual. This is in fact a hallmark of recurrent 
hypoglycaemia where repeated exposure to hypoglycaemia in people 
with or without Type 1 diabetes leads to decreased symptom and 
hormonal counterregulatory responses during a subsequent episode of 
controlled hypoglycaemia (Figure 4) [16, 30]. 
2. If the stimulus is withheld, the response tends to recover over time 
(spontaneous recovery). This means that if the stimulus (hypoglycaemia) 
is withheld the response (counterregulation) should being to recover. 
Again, this has been demonstrated clinically where strict hypoglycaemia 
avoidance lead to recovery of counterregulatory responses to subsequent 
hypoglycaemia (Figure 5) [31]. 
3. If repeated series of habituation training and spontaneous recovery are 
given, habituation becomes successively more rapid. This has not been 
tested in animal or human models, but implies that a memory of the 
stress response is retained. If the thesis of this lecture is correct and 
impaired hypoglycaemia awareness does reflect a form of habituation 
then any intervention designed to prevent hypoglycaemia, educational or 
pharmacological, needs to be reinforced becaus  impaired awareness will 
develop more rapidly if that individual is exposed to hypoglycaemia again 
in the future.  
4. The more rapid the frequency of stimulation the more rapid and/ or 
pronounced its habituation.  In a study involving rodents, it was shown 
that more frequent daily hypoglycaemia over 6 weeks lead to a greater 
counterregulatory defect than intermediate exposure to hypoglycaemia 
over this period [32]. Whether repeated brief episodes of hypoglycaemia 
compared with more prolonged but less frequent episodes over an 
equivalent time period lead to a greater counterregulatory defect is 
unknown, but may explain the development of impaired awareness of 
hypoglycaemia seen with intensification of therapy. 
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5. The weaker the stimulus, the more rapid and/or pronounced is habituation. 
Strong stimuli may yield no significant habituation. This criteria does not 
appear at first to be consistent with published research where a greater 
depth of prior hypoglycaemia was shown to have more widespread 
effects on the subsequent counterregulatory response [33]. However, 
more recently, habituation to physiological stressors has been shown to 
relate more closely to the severity of the stimulus, which means it is likely 
that habituation may to some extent depend on the nature of the stimulus 
[34, 35]. 
6. The effects of habituation may proceed beyond the zero or asymptotic level. 
This means that even when the habituated response is minimal it does 
not spontaneously recover if the habituating stimulus continues, i.e. that if 
people with IAH continue to experience hypoglycaemia, then even if no 
CRR is initiated their condition will not spontaneously resolve. In the 
study performed by Powell and Colleagues in Yale University in rodents 
daily hypoglycaemia over 6 weeks profoundly suppressed the 
counterregulatory response to subsequent hypoglycaemia and there was 
no evidence of spontaneous recovery while animals were still exposed to 
hypoglycaemia [32]. Indirect evidence in support of this feature is also 
found in an early clinical study reporting that asymptomatic nocturnal 
hypoglycaemia lead to decreased responses to hypoglycaemia induced 
the following day in subjects without diabetes [36]. This means that 
humans, even if they do not produce a counterregulatory response to 
hypoglycaemia will still habituate as long as they are exposed to low 
glucose levels.  
7. Habituation of a response to a given stimulus exhibits stimulus 
generalization to other stimuli. This has also been shown for 
hypoglycaemia and might also be considered a form of cross-tolerance. 
An example of this came from the laboratory of Davis in Vanderbilt 
University where they were able to demonstrate that a prior prolonged 
moderate exercise exposure (alternate physiological stimulus) was 
shown to suppress counterregulatory responses to subsequent 
hypoglycaemia [18]. Conversely, prior hypoglycaemia was shown to 
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supress the physiological stress response to subsequent moderate 
exercise [37]. Similarly, in people with well–controlled T1D, 
catecholaminergic responses to a cold pressor test are reduced when 
compared to people without diabetes [38].  
8. Presentation of another (usually strong) stimulus results in recovery of the 
habituated response. This is a process referred to as ‘dishabituation’, 
where there is fast recovery of a habituated response as a result of the 
presentation of a novel, strong or sometimes noxious stimulus. In a recent 
study in my laboratory we tried to address this is a study in rats [39]. We 
exposed two groups of rats to recurrent episodes of moderate (approx. 
3.0 mmol/l) hypoglycaemia over 4 weeks (12 episodes in total). One 
group subsequently underwent a low intensity exercise regimen [15 mins 
“walking” pace of 5m/min with 10% incline] while the other underwent a 
high intensity regimen exercise (5 mins at walking pace followed by an 
incremental increase in speed from 5 m/min to 15m/min “running”). The 
following day all rats then underwent a controlled hyperinsulinaemic 
hypoglycaemic clamp, where glucose levels were maintained at 2.8 
mmol/l for 90 minutes and CRR responses measured. We found that in 
comparison to a control group who had not been exposed to antecedent 
hypoglycaemia, recurrent hypoglycaemia followed by low intensity 
exercise resulted, as expected, in a significant suppression of CRR . In 
contrast, following a single bout of high intensity exercise those rats who 
had undergone 4-weeks of recurrent hypoglycaemia now showed a 
normal CRR during the clamp study [39]. This very much supports the 
concept that recurrent hypoglycaemia is a habituated response; in this 
case high intensity exercise acting as the dishabituating stimulus. 
9. Upon repeated application of the dishabituatory stimulus the amount of 
dishabituation produced habituates (habituation of dishabituation). This 
final criteria has not been tested but would suggest that any therapeutic 
intervention using a single novel or strong stimulus such as high-intensity 
exercise would, in the long-term, be insufficient to restore hypoglycaemia 
awareness in the long term, although may be effective in the short-term. 
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Summary 
Hypoglycaemia remains a real and continuing problem for people with diabetes. 
Developing strategies or therapies designed to prevent or minimise 
hypoglycaemia risk is of outmost importance. Newer technologies, better insulin 
and better educational methods should all help in this respect, but limitations to 
all these approaches means we may need to consider alternative strategies and 
these will need to be based on a clear understanding of the mechanisms 
underpinning the development of IAH in diabetes. In this lecture, I propose that 
IAH may represent a form of learning called habituation; a response that at a 
cellular level may represent a biological adaptation designed to protect the 
organism from future exposure to that stressor. The problem that results from 
this biological adaptation to recurrent hypoglycaemia is that hypoglycaemia in 
types 1 and 2 diabetes develops under conditions of high systemic insulin, which 
can result in a continuing drive to lower glucose further until severe disabling 
hypoglycaemia develops.  However, recognition of the underlying processes that 
are set in motion by recurrent exposure to hypoglycaemia means that the 
development of IAH can perhaps be better understood and explained to 
individuals with diabetes and novel therapeutic approaches such as 
dishabituation and cognitive behavioural therapies can be tested. 
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Figure legends 
 
Figure 1. Prevalence of impaired awareness of hypoglycaemia in T1DM. 
Hepburn, Diabetic Med 1990; Muhlauser, Diabetes Care 1991, Pramming, Diabetic 
Med 1991, Orchard, Diabetic Med 1991, ter Braak, Diabetes Care 2000, Pedersen-
Bjergaard, Diabetologia 2003, Geddes, Diabetic Med 2008, A’Campo, Diabetologia 
2010 [5, 11, 40-43]. 
 
Figure 2. Intensive insulin therapy and type 1 diabetes result in suboptimal 
counterregulatory responses during hypoglycaemia. This study performed by 
Amiel and colleagues [12] involved infusing a low fixed dose of insulin 
continuously into two groups of people with type 1 diabetes (T1D). For those 
T1D subjects who were on conventional insulin therapy (once or twice daily 
insulin and HbA1c approx. 75 mmol /mol (9%)) the effect on plasma glucose is 
shown by the series of white circles. In contrast, for those T1D undergoing 
intensive insulin therapy (multiple daily insulin injections of CSII with HbA1c 
approx. 55 mmol/mol (7%)) the glucose levels fall much further in response to 
the same dose of insulin (black circles). As a further comparison the likely 
response of people without diabetes to the same insulin infusion is shown by the 
grey circles (this response was not part of the study and is inserted for 
illustrative purposes only). The difference between people with and without 
diabetes is thought to primarily reflect loss of alpha cell glucagon secretion in 
T1D, while the difference between conventional and intensively-treated T1D 
results mainly from defective catecholamine secretion.    
  
Figure 3. This illustrates the counterregulatory response to low glucose in an 
individual who does not have diabetes in comparison to someone with Type 1 
diabetes and impaired awareness of hypoglycaemia (IAH).  The individual 
without diabetes when exposed to low glucose responds in a step-wise manner, 
first switching of endogenous insulin secretion then hypoglycemia stimulates 
glucagon and other counterregulatory hormone release followed by symptom 
awareness of hypoglycemia and then cognitive dysfunction. In contrast in those 
subjects with type 1 diabetes and IAH, insulin cannot be switched off and the 
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counterregulatory and symptom responses are both diminished in intensity and 
occur at lower glucose levels. The net effect is that the window between 
recognition of hypoglycemia and the ability to take action before cognition is 
significantly impaired is reduced leading to a much higher risk of severe 
hypoglycemia. 
 
Figure 4. Habituation: Criteria ♯1. Given that a particular stimulus elicits a 
response, repeated applications of that stimulus result in a decreased response 
(Habituation). This figure shows the seminal work of Heller in 1991 [16] 
demonstrating how antecedent hypoglycemia (light grey bars), compared to 
antecedent euglycaemia (dark grey bars) led to a marked suppression of the 
adrenaline response to hypoglycaemia induced 24h hrs later. This is 
characteristic of a habituated response. 
 
Figure 5. Habituation: Criteria ♯2. If the stimulus is withheld, the response tends 
to recover over time (spontaneous recovery). In this study by Cranston and 
colleagues a small group of subjects with type 1 diabetes were studied before 
and after 4.1 (1.1) months' of strict hypoglycaemia avoidance [31]. Responses to 
the initial hypoglycaemia challenge were small and only started when plasma 
glucose was significantly lower than the 2.8 (0.1) mmol/L. After hypoglycaemia 
avoidance hormone responses were greater and initiated at higher glucose 
levels.  
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